Status:
COMPLETED
Safety of ALK Ragweed Tablet
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults
Eligibility Criteria
Inclusion
- Ragweed pollen induced rhinoconjunctivitis
- Adults of either sex (18-50 years of age)
- Positive skin prick test to ragweed
Exclusion
- Previous treatment with immunotherapy
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00330083
Start Date
May 1 2006
Last Update
September 21 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Healthcare Discoveries Inc.
San Antonio, Texas, United States, 78229